Spectral Medical (TSE:EDT) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Spectral Medical is nearing completion of their Tigris trial for sepsis treatment with 126 of the targeted 150 patients already enrolled, and with a bolstered balance sheet, they are poised to finalize the trial. The company has shown a record enrollment rate in recent months and is working closely with their commercialization partner, Baxter, in anticipation of a successful trial outcome and subsequent FDA approval.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.